A stark contrast emerges between the survival rates of placebo and treatment groups, highlighting the importance of overall survival as a metric in oncology. The discussion reveals the troubling trend of drugs marketed for minimal extensions in median survival, often at exorbitant costs, raising ethical concerns about the pharmaceutical industry. Additionally, the impact of treatment on patients' quality of life and the dignity of dying is explored, emphasizing the complex decisions faced by patients and their families.
